Robert W. Baird Forecasts Strong Price Appreciation for Qiagen (NYSE:QGEN) Stock

Qiagen (NYSE:QGEN) had its target price upped by research analysts at Robert W. Baird from $50.00 to $52.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price objective points to a potential upside of 3.95% from the company’s current price.

A number of other equities analysts have also recently issued reports on the stock. Stifel Nicolaus set a $40.00 price target on shares of Qiagen in a research note on Friday, August 7th. Citigroup restated a “neutral” rating and set a $45.00 price objective (up from $38.00) on shares of Qiagen in a research note on Monday, August 10th. JPMorgan Chase & Co. lifted their target price on shares of Qiagen from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. Barclays set a $40.00 target price on shares of Qiagen and gave the stock an “equal weight” rating in a report on Friday, August 7th. Finally, Weiss Ratings upgraded shares of Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 11th. Five research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $44.68.

Qiagen Stock Up 2.3%

Shares of NYSE:QGEN opened at $50.02 on Thursday. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. The stock has a fifty day simple moving average of $44.15 and a two-hundred day simple moving average of $40.51. Qiagen has a 12-month low of $32.53 and a 12-month high of $57.81. The stock has a market capitalization of $10.31 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 4.87 and a beta of 0.61.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The firm had revenue of $535.04 million for the quarter, compared to analysts’ expectations of $527.50 million. During the same period in the prior year, the firm posted $0.60 earnings per share. The company’s quarterly revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, research analysts anticipate that Qiagen will post 2.43 earnings per share for the current fiscal year.

Institutional Trading of Qiagen

Several large investors have recently modified their holdings of the company. Crossmark Global Holdings Inc. bought a new position in shares of Qiagen in the third quarter valued at about $363,000. Quadrant Capital Group LLC raised its stake in Qiagen by 2.4% during the third quarter. Quadrant Capital Group LLC now owns 42,660 shares of the company’s stock worth $1,938,000 after acquiring an additional 1,003 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Qiagen by 61.4% in the 3rd quarter. Nisa Investment Advisors LLC now owns 7,533 shares of the company’s stock valued at $330,000 after acquiring an additional 2,867 shares during the last quarter. Cordatus Wealth Management LLC acquired a new stake in Qiagen during the 3rd quarter worth approximately $678,000. Finally, Assenagon Asset Management S.A. lifted its holdings in Qiagen by 1.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 15,722 shares of the company’s stock worth $691,000 after buying an additional 286 shares during the period. Institutional investors own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.